Perspective Therapeutics, Inc. (CATX)

Several events have impacted Perspective Therapeutics, Inc. (CATX) stock price in the past six months. The company reported Q3 and Q2 2025 earnings per share (EPS) of -0.350 USD and -0.290 USD, respectively. Perspective Therapeutics presented updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET at the 2026 ASCO Gastrointestinal Cancers Symposium. The company announced participation in various conferences and investor events between October and December 2025. Several analysts have reiterated "Buy" ratings for CATX, though price targets have fluctuated. As of January 6, 2026, the share price was $2.81, a decline of 24.46% from $3.72 on January 7, 2025.

Direct information on the demand seasonality for Perspective Therapeutics, Inc.'s specific products and services is not explicitly detailed. Analysis of CATX's seasonal charts over the past 19 years suggests that a "Buy Date" of November 10 and a "Sell Date" of January 31 has resulted in a geometric average return of 15.88% above the S&P 500 Total Return Index. Buying CATX stock in January has historically shown the highest probability of a positive return (70%), while October has the lowest (10%).

Perspective Therapeutics, Inc. (CATX) is a clinical-stage radiopharmaceutical development company focused on pioneering advanced treatment applications for various cancers. The company operates within the Healthcare sector, specifically in the Medical Devices and Medical/Dental Instruments industries. Perspective Therapeutics' core technology utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver potent radiation directly to cancer cells through specialized targeting peptides. The company's major products and drug candidates include VMT-α-NET, VMT01, PSV359, and PSV4XX.

Perspective Therapeutics, Inc. is headquartered in Seattle, Washington, United States.

Perspective Therapeutics appears to have a generally positive or stable brand reputation within the financial and medical communities, primarily driven by its clinical progress and analyst coverage. The company consistently receives "Buy" or "Strong Buy" ratings from various analysts, indicating confidence in its market position and potential growth. Regular announcements regarding clinical trial data and participation in major medical conferences contribute to a perception of active research and development. The clinical trial collaboration agreement with Bristol Myers Squibb also enhances its reputation.

Perspective Therapeutics, Inc. (CATX) has a significant institutional ownership, with 54.66% to 57.40% of its stock owned by institutional investors. Major institutional owners include Fmr Llc, BlackRock, Inc., and Vanguard Group Inc. Information on major individual owners is not as readily available.